Vanda Pharmaceuticals (LTS:0LKB) Cyclically Adjusted FCF per Share: $0.07 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LKB Vanda Pharmaceuticals Inc LTS:0LKB
73 GF Score
Price $5.05
GF Value $5.36
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Cyclically Adjusted FCF per Share?

Vanda Pharmaceuticals LTS:0LKB -1.75% 73 Cyclically Adjusted FCF per Share is $0.07 as of Jun. 2026. GuruFocus rates LTS:0LKB with a GF Score™ of 73/100 and a GF Value™ of $5.36 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was $-0.519. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.07 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Vanda Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Vanda Pharmaceuticals was 64.30% per year. The lowest was -126.80% per year. And the median was 8.25% per year.

As of today (2026-08-09), Vanda Pharmaceuticals's current stock price is $5.0501. Vanda Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $0.07. Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 72.14.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Vanda Pharmaceuticals was 1885.00. The lowest was 10.90. And the median was 29.83.


Vanda Pharmaceuticals  (LTS:0LKB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=5.0501/0.07
=72.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Vanda Pharmaceuticals was 1885.00. The lowest was 10.90. And the median was 29.83.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 -0.15 0.20 0.39 0.20

Vanda Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.24 0.20 0.11 0.07

LTS:0LKB vs LYEL, ZNTL, PROK: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


LTS:0LKB
73GF Score
Vanda Pharmaceuticals Inc LTS:0LKB
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vanda Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.519/333.9520*333.9520
=-0.519

Current CPI (Jun. 2026) = 333.9520.

Vanda Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.029 241.428 0.040
201612 -0.027 241.432 -0.037
201703 -0.131 243.801 -0.179
201706 -0.064 244.955 -0.087
201709 0.040 246.819 0.054
201712 0.073 246.524 0.099
201803 0.031 249.554 0.041
201806 -0.383 251.989 -0.508
201809 0.156 252.439 0.206
201812 0.276 251.233 0.367
201903 0.175 254.202 0.230
201906 0.371 256.143 0.484
201909 0.105 256.759 0.137
201912 0.177 256.974 0.230
202003 -0.023 258.115 -0.030
202006 0.432 257.797 0.560
202009 0.165 260.280 0.212
202012 0.330 260.474 0.423
202103 0.160 264.877 0.202
202106 0.329 271.696 0.404
202109 0.165 274.310 0.201
202112 0.463 278.802 0.555
202203 0.071 287.504 0.082
202206 0.097 296.311 0.109
202209 0.223 296.808 0.251
202212 0.156 296.797 0.176
202303 0.553 301.836 0.612
202306 -0.231 305.109 -0.253
202309 -0.036 307.789 -0.039
202312 -0.069 306.746 -0.075
202403 0.131 312.332 0.140
202406 -0.121 314.175 -0.129
202409 -0.253 315.301 -0.268
202412 -0.035 315.605 -0.037
202503 -0.574 319.799 -0.599
202506 -0.264 322.561 -0.273
202509 -0.538 324.800 -0.553
202512 -0.499 324.054 -0.514
202603 -1.016 330.213 -1.028
202606 -0.519 333.952 -0.519

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.07 mean?
Vanda Pharmaceuticals (LTS:0LKB) has a Cyclically Adjusted FCF per Share of $0.07 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Vanda Pharmaceuticals' current Cyclically Adjusted FCF per Share is $0.07. Overall, Vanda Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Cyclically Adjusted FCF per Share compare to LYEL and ZNTL?
Vanda Pharmaceuticals' Cyclically Adjusted FCF per Share of $0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Cyclically Adjusted FCF per Share is $0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (LTS:0LKB) is currently considered Fairly Valued. The stock's GF Value™ is $5.36, compared to a current price of $5.05 — trading 5.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.07. Vanda Pharmaceuticals' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Vanda Pharmaceuticals (LTS:0LKB), the current Cyclically Adjusted FCF per Share is $0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (LTS:0LKB) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued. The current stock price of $5.05 is trading 5.8% below its estimated GF Value™ of $5.36. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0LKB:

  • Cyclically Adjusted FCF per Share: $0.07
  • GF Value™: $5.36 vs. price of $5.05 (5.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the LTS:0LKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USAVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
73GF Score

Get the complete analysis for LTS:0LKB

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.05
Price
$5.36
GF Value